---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-087243"
form_type: "8-K"
ticker: "MOVE"
cik: "0001734750"
company_name: "Corvex, Inc."
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:36:27.246001+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Movano Health to launch Evie Ring Nov 20; reports Q3 net loss $9.0M

## Summary
- Evie Ring launches Nov 20 at $269 with no subscription; shipping expected by year-end.
- Blood pressure SoC met FDA accuracy standards in clinical study; pivotal trial planned.
- FDA requested additional info on Evie Ring pulse oximeter 510(k); reply planned Q1 2024.
- Priced $3.6M public offering of 4.2M shares at $0.85; expected close Nov 17.
- Q3 net loss $9.0M ($0.18 loss per share); no revenue; pro forma cash $10.8M.

## SEC filing metadata
- accession: 0001213900-23-087243
- form_type: 8-K
- ticker: MOVE
- cik: 0001734750
- company_name: Corvex, Inc.
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1734750/000121390023087243/0001213900-23-087243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1734750/000121390023087243/ea188087-8k_movanoinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-087243
- JSON: https://secwatch.observer/filing/0001213900-23-087243.json
- Plain text: https://secwatch.observer/filing/0001213900-23-087243.txt

## Key facts
- Earnings Releases
  Corvex, Inc. reported the three months ending September 30, 2023 results: net income $9.0 million, EPS $(0.18) per basic and diluted share.
  - Period: the three months ending September 30, 2023
  - Net income: $9.0 million
  - EPS: $(0.18) per basic and diluted share
  - Result: reported results
  source text: Movano Health reported a net loss of $9.0 million and a loss of $(0.18) per basic and diluted share, in the third quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1734750/000121390023087243/0001213900-23-087243-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.